{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-021642","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.688525+00:00","generated_at":"2026-06-13T22:47:32.440049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evofem Q1 net product revenue up 37% to $5.8M; operating loss down 88%; reaffirms path to EBITDA break-even","bullets":["Phexxi net product sales $5.8M (+37% YoY); total operating expenses $9.4M (-72% YoY).","Loss from operations decreased 88% to $3.6M; net loss $(2.4)M ($1.85/share) vs $(32.0)M ($360.25/share).","Cash at March 31: $1.5M (restricted+unrestricted) down from $4.8M; on track for quarterly EBITDA break-even by year-end 2023.","Appointed Ivy Zhang as CFO effective April 13, 2023; effectuated reverse stock split on May 18, 2023.","Filed patent infringement suit against Padagis on June 1, 2023; triggers 30-month FDA stay on generic Phexxi approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-021642","json":"https://secwatch.observer/filing/0001493152-23-021642.json","markdown":"https://secwatch.observer/filing/0001493152-23-021642.md","text":"https://secwatch.observer/filing/0001493152-23-021642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223021642/0001493152-23-021642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223021642/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:47:32.440049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ce106f7e177a645a73f1d009348b227db30f32f","claim":"Evofem Biosciences, Inc. reported first quarter of 2023 results: revenue $5.8 million, net income $(2.4) million, EPS $(1.85) per share. Guidance reaffirmed.","evidence_excerpt":"contraceptive gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) . Highlights for and since the quarter include: ● Increased Phexxi net product sales 37% to $5.8 million. ● Reduced total operating expenses 72% to $9.4 million. ○ Implemented measures in March 2023 to further decrease operating expenses. ● Loss from operations decreased 88% to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223021642/0001493152-23-021642-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$5.8 million"},{"label":"Net income","value":"$(2.4) million"},{"label":"EPS","value":"$(1.85) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}